Formulation and In-Vitro Evaluation of Buclizine Buccoadhesive Tablets

Buclizine is an antihistamine that is used to treat motions sickness, especially to prevent and treat symptoms such as abdominal pain, dizziness, nausea, vomiting, headaches, etc. It may also be used either alone or in a combination with other medicines for the treatment of hay fever and other allergic conditions. These dosages form make close contact with buccal mucosa, avoid first- pass metabolism, increase absorption and patient compliance, results in an enhanced drug bioavailability. Buccal adhesive tablets were prepared by direct compression. Carbopol 940 and Sodium Alginate was used in different ratios and also in combination. Formulated 10 batches were evaluated for physical parameter, swelling studies, bioadhesion studies, and in-vitro drug release and in-vitro drug permeation. Bioadhesion studies were carried out to determine mucoadhesive potential of prepared tablets. Tablets were evaluated for in-vitro drug release for 6 hrs, using USP type II method and. From these results it can be concluded that formulation batch F6 was most promising comprising of 1:4 ratio of Sodium Alginate. The best fit model for the optimized batch F6 was zero order having R value 0.9889 and K value is 0.2542.  Keywords: Buclizine, Carbopol 940, Sodium Alginate, buccal tablet, in-vitro drug permeatio